Results 221 to 230 of about 1,995 (245)

Strengthening global preparedness and response to arboviral disease threats: a call to action. [PDF]

Lancet Infect Dis
WHO Global Arbovirus Initiative Technical Advisory Group.
europepmc   +1 more source

Qdenga-induced dengue caused by minor DENV-2 subvariant(s) in the vaccine, with two amino acid substitutions in the E protein. [PDF]

J Travel Med
Pettersson JH, Tibbelin E, Heyman G, Aarum J, Karlsson Lindsjö O, Blom K, Sondén K, Klingström J.   +7 more
europepmc   +1 more source

The Forefront of Dengue Control. [PDF]

Braz J Infect Dis
Goldani LZ.
europepmc   +1 more source

Evaluating the economic burden of dengue in Sri Lanka: A systematic review of costs from 2010 to 2024. [PDF]

IJID Reg
Wickramasinghe HT, Ranawaka R, Kalra P, Hanley R, Gallagher E.   +4 more
europepmc   +1 more source

Isolation and Characterization of 5-(1-Hydroxyethyl)-Dihydro-2-Furanone from <i>Angiopteris evecta</i> with Potent Anti-Inflammatory and Anti-Leukemic Activities. [PDF]

Int J Mol Sci
Rueankham L, Viriyaadhammaa N, Yin W, Liu Y, Chiampanichayakul S, Rungrojsakul M, Katekunlaphan T, Okonogi S, Saiai A, Iwasaki A, Chick CN, Usuki T, Anuchapreeda S.   +12 more
europepmc   +1 more source

Estado actual de las vacunas contra el dengue, confoco en TAK-003 (Qdenga®)

Archivos Argentinos de Pediatria
openaire   +1 more source

Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial

Vaccine
Exploring time-to-onset of efficacy of the live-attenuated dengue vaccine TAK-003 is important for individuals living in, or traveling to, dengue-endemic areas. This protocol-defined exploratory analysis of the Tetravalent Immunization against Dengue Efficacy Study (TIDES) investigated TAK-003's onset of efficacy after the first and before the second ...
Shibadas Biswal, Vianney Tricou, Nicolas Folschweiller   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

A new dengue vaccine (TAK-003) now WHO recommended in endemic areas; what about travellers?

Journal of Travel Medicine, 2023
Qdenga (Takeda) is now WHO recommended for residents of highly endemic areas. Travellers from dengue non-endemic countries with previous travel-related dengue (any serotype) will benefit from TAK-003 vaccination to prevent a secondary dengue infection during future dengue risk travel.
exaly   +3 more sources